Vaccination against Leishmania major in a CBA mouse model of infection: Role of adjuvants and mechanism of protection

Parasite Immunology

Volumn 21, Issue 9, 1999, Pages 461-473

  Rivier, D ^a   Bovay, P ^a   Shah, R ^a   Didisheim, S ^a   Mauel J ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adjuvants; Gp63; Leishmania; Vaccination

Indexed keywords

ADJUVANT; LEISHMANIA VACCINE; LIVE VACCINE; MEMBRANE PROTEIN; OVALBUMIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FOOT PAD; INOCULATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; PROMASTIGOTE; RADIOIODINATION; TAIL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DISEASE MODELS, ANIMAL; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MACROPHAGES; MATCHED-PAIR ANALYSIS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED CBA; OVALBUMIN; PROTOZOAN VACCINES; T-LYMPHOCYTES; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

ANIMALIA; CELL FUSING AGENT VIRUS; LEISHMANIA MAJOR; MYCOBACTERIUM BOVIS BCG; PROTOZOA;

EID: 0032778357     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3024.1999.00244.x     Document Type: Article

References (36)

1. Abdelhak S., Louzir H., Timm J. et al. (1995) Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 141, 1585
2. Alvar J., Canavate C., Gutierrez-Solar B. et al. (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years [review]. Clinical Microbiology Reviews 10, 298
3. Bahar K., Dowlati Y., Alimohammadian M.H. et al. (1996) Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clinics in Dermatology 14, 489
4. Bahr V., Stierhof Y.D., Ilg T. et al. (1993) Expression of lipophosphoglycan, high-molecular weight phosphoglycan and glycoprotein 63 in promastigotes and amastigotes of Leishmania mexicana. Molecular and Biochemical Parasitology 58, 107
5. Berens R.L. & Marr J.J. (1978) An easily prepared defined medium for cultivation of Leishmania donovani promastigotes. Journal of Parasitology 64, 160
6. Bordier C., Etges R.J., Ward J. et al. (1986) Leishmania and Trypanosoma surface glycoproteins have a common glycophospholipid membrane anchor. Proceedings of the National Academy of Sciences of the United States of America 83, 5988
7. Bouvier J., Etges R.J. & Bordier C. (1985) Identification and purification of membrane and soluble forms of the major surface protein of Leishmania promastigotes. Journal of Biological Chemistry 260, 15504
8. Ceredig R. & Corradin G. (1986) High antigen concentration inhibits T cell proliferation but not interleukin 2 production: examination of limiting dilution microcultures and T cell clones. European Journal of Immunology 16, 30
9. Connell N.D., Medina-Acosta E., McMaster et al. (1993) Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proceedings of the National Academy of Sciences of the United States of America 90, 11473
10. Corradin G., Etlinger H.M. & Chiller J.M. (1977) Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice. Journal of Immunology 119, 1048
11. Dailey M.O., Post W. & Hunter R.L. (1977) Induction of cell-mediated immunity to chemically modified antigens in guinea pigs. II. The interaction between lipid-conjugated antigens, macrophages, and T lymphocytes. Journal of Immunology 118, 963
12. Frankenburg S., Axelrod O., Kutner S. et al. (1996) Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Vaccine 14, 923-929
13. Fresno M., Kopf M. & Rivas L. (1997) Cytokines and infectious diseases. Immunology Today 18, 56
14. Gurunathan S., Sacks D.L., Brown D.R. et al. (1997) Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. Journal of Experimental Medicine 186, 1137
15. Handman E., Button L.L. & McMaster R.W. (1990) Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Experimental Parasitology 70, 427
16. Jardim A., Alexander J., Teh H.S. et al. (1990) Immunoprotective Leishmania major synthetic T cell epitopes. Journal of Experimental Medicine 172, 645
17. Kahl L.P., Scott C.A., Lelchuk et al. (1989) Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. Journal of Immunology 142, 4441
18. Lopez J.A., Reins H.A., Etges R.J. et al. (1991) Genetic control of the immune response in mice to Leishmania mexicana surface protease. Journal of Immunology 146, 1328
19. Louis J., Moedder E., Behin R. et al. (1979) Recognition of protozoan parasite antigens by murine T lymphocytes. I. Induction of specific T lymphocyte-dependent proliferative response to Leishmania tropica. European Journal of Immunology 9, 841
20. Mauel J. (1984) Intracellular parasite killing induced by electron carriers. I. Effect of electron carriers on intracellular Leishmania spp. in macrophages from different genetic backgrounds. Molecular and Biochemical Parasitology 13, 83
21. McSorley S.J., Xu D. & Liew F.Y. (1997) Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infection and Immunity 65, 171
22. Medina-Acosta E., Karess R.E., Schwartz H. et al. (1989) The promastigote surface protease (gp63) of Leishmania is expressed but differentially processed and localized in the amastigote stage. Molecular and Biochemical Parasitology 37, 263
23. Meerpohl H.G., Lohmann-Matthes M.L. & Fischer H. (1976) Studies on the activation of mouse bone marrow-derived macrophages by the macrophage cytotoxicity factor (MCF). European Journal of Immunology 6, 213
24. Nascimento E., Mayrink W., da Costa C.A. et al. (1990) Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infection and Immunity 58, 2198
25. Pham T.V. & Mauel J. (1987) Studies on intracellular killing of Leishmania major and lysis of host macrophages by immune lymphoid cells in vitro. Parasite Immunology 9, 721
26. Rivier D., Didisheim S., Etges R.J. et al. (1989) Studies on antigenicity of amphiphilic and hydrophilic forms of Leishmania major promastigote surface protease in the mouse. In Leishmaniasis: the Current Status and New Strategies for Control. Nato ASI Series. Series a, Life Sciences, ed. D.T. Hart, vol. 163, p. 423. New York, Plenum Press
27. Rivier D., Shah R., Bovay P. et al. (1993) Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunology 15, 75
28. Russell D.G. & Alexander J. (1988) Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes [published erratum appears in J Immunol (1988) 140, 2858]. Journal of Immunology 140, 1274
29. Russell D.G., Talamas-Rohana P. & Zelechowski J. (1989) Antibodies raised against synthetic peptides from the Arg-Gly-Asp-containing region of the Leishmania surface protein gp63 cross-react with human C3 and interfere with gp63-mediated binding to macrophages. Infection and Immunity 57, 630
30. Schneider P., Rosat J.P., Bouvier J. et al. (1992) Leishmania major: differential regulation of the surface metalloprotease in amastigote and promastigote stages. Experimental Parasitology 75, 196
31. Soares L.R., Sercarz E.E. & Miller A. (1994) Vaccination of the Leishmania major susceptible BALB/c mouse. I. The precise selection of peptide determinant influences CD4+ T cell subset expression. International Immunology 6, 785
32. Wysocki L.J. & Sato V.L. (1978) 'Panning' for lymphocytes: a method for cell selection. Proceedings of the National Academy of Sciences of the United States of America 75, 2844
33. Xu D. & Liew F.Y. (1995) Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84, 173
34. Xu D., McSorley S.J., Chatfield S.N. et al. (1995) Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-). Immunology 85, 1
35. Yang D.M., Fairweather N., Button L.L. et al. (1990) Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper I cells and protective immunity against leishmaniasis. Journal of Immunology 145, 2281
36. Yang D.M., Rogers M.V. & Liew F.Y. (1991) Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology 72, 3